• Explore /
  • Poster
  • / A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer.

A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer.

Abstract Poster

Authors

null

Mark N. Stein

Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY

Mark N. Stein , Tanya B. Dorff , Oscar B. Goodman Jr., Roby Antony Thomas , Michael H. Silverman , Matthew Guo , Catherine R Aversa , Raphael Clynes , Barbara Hickingbottom , Jolene S Shorr

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT05005728

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5097)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5097

Abstract #

TPS5097

Poster Bd #

278a

Abstract Disclosures

Similar Posters

First Author: Sumit Kumar Subudhi

First Author: Benedito A. Carneiro

First Author: Ruben Raychaudhuri

First Author: Louise Kathleen Kostos